TABLE 2.

Summary of adverse experiences

Treatment groupNo. (%) of patients experiencing adverse event
ClinicalLaboratory
Drug relatedaSerious and drug relatedaTherapy stopped due to a serious drug-relateda clinical adverse eventDied from any causeDrug relatedaSerious and drug relatedaTherapy stopped due to a serious drug-relateda laboratory adverse event
Caspofungin acetate, 35 mg (n = 34)17 (50)b0 (0)0 (0)3 (9)16 (48)0 (0)0 (0)
Caspofungin acetate, 50 mg (n = 34)12 (35)b0 (0)0 (0)1 (3)15 (44)c0 (0)0 (0)
Caspofungin acetate, 70 mg (n = 37)17 (46)b0 (0)0 (0)3 (8)13 (35)b0 (0)0 (0)
Amphotericin B, 0.5 mg/kg (n = 35)34 (97)3 (9)1 (3)5 (14)25 (71)1 (3)0 (0)
All patients (n = 140)d80 (57)3 (2)1 (1)12 (9)69 (50)1 (1)0 (0)
  • a Determined by the investigator to be possibly, probably, or definitely drug related.

  • b P ≤ 0.01 versus amphotericin B.

  • c P ≤ 0.05 versus amphotericin B.

  • d Only 33 of the 34 patients in the caspofungin, 35 mg, group had follow-up laboratory results and were included in the tabulation of laboratory adverse events.